Indirect quantification of EVs in a subset of samples employing a CD63 ELISA (Her2+ (n = 78), TNBC (n = 40), and healthy controls (n = 10)) revealed a significant increase in EVs in both breast cancer groups compared to controls, with a higher (non-significant) level also reported in Her2+ compared to TNBC patients [19]. The gene discussed is ERBB2; the disease is breast carcinoma.